Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Expression levels of SPDL1 mRNA in PAAD tumors and normal tissues. A SPDL1 mRNA expression in TCGA cohort. B SPDL1 mRNA expression in GSE15471 cohort. C SPDL1 mRNA expression in GSE62165 cohort. D The graph presents a bar chart of SPDL1 expression distribution across PAAD cell lines, Both the height and color of the bars indicate the magnitude of SPDL1 expression, with the median serving as the cutoff point. P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Representative immunohistochemical images showing SPDL1 expression in tumor-adjacent tissues and pancreatic adenocarcinoma (PAAD) tissues. A SPDL1 staining in adjacent tissues. B SPDL1 weak staining in PAAD tissues. C SPDL1 strong staining in PAAD tissues. The expression of SPDL1 in PAAD tissues with different Ki-67 expression. *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Immunohistochemical staining, Expressing, Staining

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Single-cell expression analysis of SPDL1 in PAAD. A The UMAP plot of single-cell clustering in GSE148673 . B UMAP plot showing SPDL1 expression distribution across distinct cell types in GSE148673 . C AUCell score for tumor proliferation signature in different cells in GSE148673 . D The UMAP plot of single-cell clustering in GSE154778 . E UMAP plot showing SPDL1 expression distribution across distinct cell types in GSE154778 . F AUCell score for tumor proliferation signature in different cells in GSE154778 . G SPDL1 expression across distinct cell types in GSE148673 . H Differential analysis of tumor proliferation-related signaling pathways between SPDL1-positive and SPDL1-negative cell groups in the GSE148673 . I SPDL1 expression across distinct cell types in GSE148673 . J Differential analysis of tumor proliferation-related signaling pathways between SPDL1-positive and SPDL1-negative cell groups in the GSE148673

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Single Cell, Expressing, Protein-Protein interactions

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: The correlation of SPDL1 mRNA expression with clinical parameters from the TCGA cohort, including ( A ) Age, ( B ) Sex, ( C ) T stage, ( D ) N stage, ( E ) M stage, ( F ) TNM stage. *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Expression is associated with the prognosis of PAAD patients. A Kaplan-Meier survival curves of OS between high and low SPDL1 expression groups. B Kaplan-Meier survival curves of DSS between high and low SPDL1 expression groups. C Kaplan-Meier survival curves comparing PFI between high and low SPDL1 expression groups. D Univariate and Multivariate Cox regression analysis (overall survival) for prognostic factors in PAAD. E Independent risk factors were evaluated for OS using multivariate Cox regression and were combined into the nomogram model. F ROC curves and nomogram AUC values for predicting 1-, 2-, and 3-year OS. G Calibration charts for the nomogram depicting 1-year, 2-year and 3-year OS. H DCA for the nomogram depicting 1-year OS. I DCA for the nomogram depicting 2-year OS. J DCA for the nomogram depicting 3-year OS

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: GSEA and GSVA analysis. A GSEA analysis revealed that the tumor proliferation pathway is enriched in the SPDL1-high expression group. B Relationship between SPDL1 expression and tumor proliferation score

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Effect of SPDL1 Silencing on PAAD Cell Proliferation in PAAD. A Western blot analysis showing that SPDL1 protein expression was significantly reduced in PANC-1 cells following transfection with si-SPDL1 compared with control group. B CCK-8 assays demonstrated that SPDL1 silencing markedly inhibited cell viability in PANC-1 cells over time (24, 48, and 72 h), with significant reduction at 24 h compared with control group. C , D Colony formation assays indicated that SPDL1 knockdown significantly reduced the number of colonies formed. E , F EdU incorporation assay reveals SPDL1 knockdown significantly reduced the ratio of cell proliferation. For ( A ), ( B ), ( D ), and ( E ): *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Western Blot, Expressing, Transfection, Control, CCK-8 Assay, Knockdown

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: Knockdown expression of SPDL1 inhabited the migration and invasion of PANC-1 cells. A Wound healing assays showed that SPDL1 knockdown significantly delayed wound closure at 24 h, indicating impaired migration. B Transwell invasion assays showed that SPDL1 silencing significantly decreased the number of invading PANC-1 cells. For ( A ) and ( B ): *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Knockdown, Expressing, Migration

Journal: Discover Oncology

Article Title: SPDL1 is associated with prognosis and tumor proliferation in pancreatic adenocarcinoma

doi: 10.1007/s12672-026-04576-2

Figure Lengend Snippet: SPDL1 activates the AKT/mTOR signaling pathway. A Gene Set Enrichment Analysis (GSEA) based on TCGA dataset revealed that the PI3K/AKT/mTOR signaling pathway was significantly enriched in the SPDL1 high-expression group relative to the SPDL1 low-expression group. B Western blot assay was performed to detect the protein expression levels of AKT, phosphorylated AKT (p-AKT), mTOR, and phosphorylated mTOR (p-mTOR) in PANC-1 cells following different transfection treatments. For ( B ): *** p < 0.001, ** p < 0.01, * p < 0.05

Article Snippet: PVDF membranes blocked with 5% nonfat milk were incubated with primary antibodies against SPDL1 (BOSTER, A12722-2), AKT1 (BOSTER, BM4390), phospho-AKT1 (S129) (BOSTER, BM4744), mTOR (BOSTER, BM4182), phospho-mTOR (S2448) (BOSTER, BM4840) and GAPDH (BOSTER, BM1623).

Techniques: Expressing, Western Blot, Transfection

Journal: Disease Models & Mechanisms

Article Title: C-C motif receptor 2 is a core profibrotic factor in uremic cardiomyopathy

doi: 10.1242/dmm.052395

Figure Lengend Snippet: CCR-2 blockade suppresses left ventricular (LV) fibrosis in MNx-induced UC. (A) Schedule of INCB3344 administration. w, weeks. (B) CCR-2 inhibition significantly alleviated LV fibrosis (scale bars: 50 μm), and slightly reduced myocyte cross-section area. 2-week CCR-2 treatment obtained similar effects but without causing reduced myocyte cross-section area (scale bars: 50 μm, n =360 cells per group). (C) UC model with INCB3344 treatment demonstrated larger heart (Gross, scale bar: 2 mm), slightly reduced LV wall thickness, increased LV diameter [B-mode, scale bar: 2 mm; M-mode, scale bars: 1 mm (longitudinal) and 100 ms (transverse); WGA, scale bar: 50 μm] and compromised LV systolic function. However, 2-week CCR-2 treatment did not induce LV dilation and compromised LV systolic function. Sham (sham group), n =6; MNx, n =6; MNx+5w INCB3344 (modified nephrectomy group with 5-week INCB3344 injection), n =6; MNx+2w INCB3344 (modified nephrectomy group with 2-week INCB3344 injection), n =6. One-way ANOVA followed by Tukey's multiple comparisons test or Kruskal–Wallis test followed by Dunn's multiple comparisons test was used. * P <0.05, ** P <0.01.

Article Snippet: For CCR-2 analysis, LV tissue slides were fixed in EDTA pH 9.0 solution at 95°C for 10 min after rehydration, followed by incubation with peroxidase blocking buffer (ZSGB-BIO Co.; ZLI-9311) for 15 min. After PBS washing, slides were incubated with QuickBlock Blocking Buffer for Immunol Staining (Beyotime Biotechnology Co., Ltd.) for 30 min. Antibodies against CCR-2 (1:100; Proteintech Group, Inc.; 16153-1-AP) were applied overnight at 4°C, followed by incubation with goat anti-rabbit IgG (ZSGB-BIO Co.; PV-6000) for 30 min.

Techniques: Inhibition, Modification, Injection

Journal: Disease Models & Mechanisms

Article Title: C-C motif receptor 2 is a core profibrotic factor in uremic cardiomyopathy

doi: 10.1242/dmm.052395

Figure Lengend Snippet: INCB3344 reduces LV inflammation and may increase LV residual macrophages. (A) Inhibition of CCR-2 downregulated the expression of markers of inflammation. (B) Inhibition of CCR-2 upregulated CCR-2 − residual macrophage markers in LV tissues. (C) Immunofluorescence showed increased infiltration of F4/80 + , TIMD-4 + and CD163 + cells in LV tissues after INCB3344 injection, and some F4/80 + cells were co-stained with CD163 and TIMD-4. White arrows indicate F4/80 + TIMD-4 + CD163 + cells (scale bar: 100 μm). (D) Flow cytometry showed that INCB3344 increased the proportion of CD163 + TIMD-4 + cells in F4/80 + cells derived from LV tissues. Sham, n =6; MNx, n =6; MNx+5w INCB3344, n =6; MNx+2w INCB3344, n =6. One-way ANOVA followed by Tukey's multiple comparisons test or Kruskal–Wallis test followed by Dunn's multiple comparisons test was used. * P <0.05, ** P <0.01.

Article Snippet: For CCR-2 analysis, LV tissue slides were fixed in EDTA pH 9.0 solution at 95°C for 10 min after rehydration, followed by incubation with peroxidase blocking buffer (ZSGB-BIO Co.; ZLI-9311) for 15 min. After PBS washing, slides were incubated with QuickBlock Blocking Buffer for Immunol Staining (Beyotime Biotechnology Co., Ltd.) for 30 min. Antibodies against CCR-2 (1:100; Proteintech Group, Inc.; 16153-1-AP) were applied overnight at 4°C, followed by incubation with goat anti-rabbit IgG (ZSGB-BIO Co.; PV-6000) for 30 min.

Techniques: Inhibition, Expressing, Immunofluorescence, Injection, Staining, Flow Cytometry, Derivative Assay

Journal: Microorganisms

Article Title: Monosodium Glutamate Inhibits Pseudomonas aeruginosa -Induced Acute Lung Injury by Targeting the Type III Secretion Systems and Modulating Host Immunity

doi: 10.3390/microorganisms14030725

Figure Lengend Snippet: KEGG pathway enrichment analysis and key protein expression in P. aeruginosa -induced acute lung injury (ALI) in mice. ( A ) KEGG pathway enrichment of differentially expressed genes between the ALI model and control groups; ( B ) protein levels of phospho-JNK, p-p38, p-p65, TLR4, and MyD88 in lung tissues compared between the ALI model and control groups by Western blot analysis (β-actin loading control); ( C ) comparison of protein levels (p-JNK, p-p38, p-p65, TLR4, MyD88) in lung tissues between the model and MSG-treated groups, as detected by Western blot (β-actin control) (n = 12 samples per group; data represent means ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).

Article Snippet: The antibodies for phospho-NF-κB p65 (82335-1-RR), p-65 (80979-1-RR), phospho-P38 (14064-1-AP), phospho-JNK (80024-1-RR), MyD88 (23230-1-AP), TLR-4 (19811-1-AP), P38 (14064-1-AP), JNK (51153-1-AP), and β-actin (66009-1-Ig) were purchased from ProteinTech Group (Wuhan, China).

Techniques: Expressing, Control, Western Blot, Comparison